Research programme: lung cancer therapeutics and diagnostics - A*STAR/GlaxoSmithKline
Latest Information Update: 16 Jul 2016
At a glance
- Originator Agency for Science, Technology and Research
- Class Monoclonal antibodies; Monoclonal antibody diagnostics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Lung-cancer in Singapore
- 16 Jul 2016 No recent reports of development identified for research development in Lung-cancer(Diagnosis) in Singapore
- 06 Nov 2012 Early research in Lung cancer in Singapore (unspecified route)